There are 3 Cochrane database reviews of treatment for mild-to-moderate hypertension during pregnancy.S10.2.2-10 S10.2.2-12 With regard to the treatment of mild-to-moderate hyperten- sion (SBP of 140 169 or DBP of 90 109 mm Hg), anti- hypertensive treatment reduces the risk of progression to severe hypertension by 50% compared with placebo but has not been shown to prevent preeclampsia, preterm birth, small for gestational age, or infant mortality. Beta blockers and CCBs appear superior to alpha-methyldopa in prevent- An earlier review of 2 small trials did not show improved outcomes with more comprehen- sive treatment of BP to a target of <130/80 mm Hg.S10.2.2-11 Consistent with the results of the Cochrane reviews, a large multinational RCT of treatment in pregnant women with mild-to-moderate hypertension also reported that treat- ment prevented progression to severe hypertension, but other maternal and infant outcomes were unaffected by the intensity of treatment.S10.2.2-13 An earlier review confined to assessing the effect of beta blockers found them generally safe and effective but of no benefit for newborn outcomes, either in placebo-controlled studies or when compared with other antihypertensive agents. There was a suggestion that beta-blocker therapy might be associated with small for gestational age and neonatal bradycardia.S10.2.2-12 The larg- est experience for beta blockers is with labetalol; the larg- est experience for CCBs is with nifedipine. Methyldopa and hydralazine may also be used. 